Skip to content

Released May 6, 2025, after the close

10-Q filed May 6, 2025, 36 days after period end · 0000950170-25-064606

Q1 2025 · 10-Q
Revenue$20.22M−55.6% vs Q1 2024+2,172.1% vs Q4 2024
Net Income-$26.03MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.07N/M vs Q1 2024no prior Q4 2024 on file
Gross Profit$11,049,000−54.3%
Operating Income-$26,970,000N/M
Operating Cash Flow-$30,283,000N/M
Free Cash Flowderived-$35,337,000N/M
Margins · derived
Gross margin54.6%+1.5 pt vs Q1 2024
Operating margin-133.4%−1.2 pt vs Q1 2024
Net margin-128.7%−58.1 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Revenue$20.22M$45.54M$25.12M$26.50M
Net Income-$26.03M-$32.16M-$16.84M-$76.29M
EPS Diluted-$0.07-$0.27-$0.21-$0.99

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR